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Background: The appropriate care for people with cardiovascular risk factors can reduce morbidity and mortality.
One strategy for improving the care for these patients involves the implementation of evidence-based guidelines.
To date, little research concerning the impact of such implementation strategies in our setting has been published.
Aims. To evaluate the effectiveness of a multifaceted tailored intervention in the implementation of three
cardiovascular risk-related guidelines (hypertension, type 2 diabetes and dyslipidemia) in primary care in the Basque
Health Service compared with usual implementation.
Methods/Design: A two-year cluster randomized clinical trial in primary care in two districts in the Basque Health
Service. All primary care units are randomized. Data from all patients with diabetes, hypertension and those
susceptible to coronary risk screening will be analyzed.
Interventions. The control group will receive standard implementation. The experimental group will receive a
multifaceted tailored implementation strategy, including a specific web page and workshops for family physicians
and nurses.
Endpoints. Primary endpoints: annual request for glycosylated hemoglobin, basic laboratory tests for hypertension,
cardiovascular risk screening (women between 45–74 and men between 40–74 years old). Secondary endpoints:
other process and clinical guideline indicators.
Analysis: Data will be extracted from centralized computerized medical records. Analysis will be performed at a
primary care unit level weighted by cluster size.
Discussion: The main contribution of our study is that it seeks to identify an effective strategy for cardiovascular
guideline implementation in primary care in our setting.
Trial registration: Current Controlled Trials, ISRCTN88876909
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Diabetes and cardiovascular risk factors
High blood pressure, dyslipidemia and diabetes are the
main clinical conditions presented by patients with mul-
tiple morbidities [1].
Cardiovascular disease is the leading cause of death in
both the Basque Country and Spain as a whole. Despite
this, cardiovascular disease-related mortality has decreased
over the past few years due, amongst other reasons, to the
better diagnosis and treatment of cardiovascular risk fac-
tors [2].
Current data suggest that there remains significant
room for improvement in cardiovascular risk factor and
diabetes care in our setting. According to data from the
Provider Agreement in 2008 only 41.3% of diabetic pa-
tients in the Autonomous Community of the Basque
Country had a glycosylated hemoglobin (HbA1c) level of
less than 7.5%, basic analysis was performed in 44.9% of
patients and only 27% had a blood pressure of less than
140/80 mm Hg.
The almost anecdotal use of tools to calculate cardio-
vascular risk at that time suggests that statin treatment
in primary prevention is chosen on the basis of choles-
terol level rather than overall cardiovascular risk [3].
As far as hypertensive patients in our setting are con-
cerned, it is estimated that only 33% have their blood
pressure well controlled and that 46.4% do not receive
the antihypertensive agent of choice [4].
Clinical practice guidelines as a tool for improving
healthcare
The implementation of evidence-based clinical practice
guidelines (CPGs) may help to ensure that the care of
patients with cardiovascular risk factors or diabetes
complies with the best quality criteria and standards.
CPGs are statements that include recommendations
intended to optimize patient care which are informed by
a systematic review of evidence and an assessment of
the benefits and harms of alternative care options [5]. As
such, they have the potential to reduce variability and
improve healthcare [6].
In the past few years we have witnessed the consolida-
tion of a CPG program in both the Basque Country and
the Spanish National Health System as a whole that has
led to the Guiasalud program [7], the development of a
common methodology for drafting such guidelines [8]
and the availability of an increasing number of guide-
lines prepared in Spain.
Thus, in the cardiovascular field, 2008 and 2009 saw
the publication of the “Clinical practice guideline on the
management of lipids as a cardiovascular risk factor” [9],
an update to the regional “Clinical practice guideline on
arterial hypertension” [4] and the “Clinical practice
guideline on type 2 diabetes” [10], the latter of whichwas drafted within the framework of the National Health
System's Clinical Practice Guideline Program in collab-
oration with the Health Technology Assessment Agency
Osteba. These three guidelines are available from
Guiasalud [7] and have been included in the National
Guideline Clearinghouse.
Design of CPG implementation strategies
The publication and dissemination of a CPG does not,
however, ensure its application in clinical practice, there-
fore effective and viable implementation plans for the
organizational context at which it is aimed must be de-
signed. Implementation must be considered to be a
planned process whose main characteristics are dyna-
mism and uniqueness [6].
It is important that guideline implementation inter-
ventions are designed in accordance with a coherent the-
oretical foundation, a body of evidence to support them
and taking into account the barriers and facilitators of
the local setting [6,11-13].
Theoretical foundation
Grol’s 10-step model [11] is a theoretical reference for
guideline implementation [6]. This model brings to-
gether elements from different disciplines, such as the
diffusion of innovation theory [14], the reasoned action
theory [15] and social cognitive theory [16], and postulates
that professionals pass through different phases or stages
(orientation, insight, acceptance, change and maintenance)
when achieving a change, with specific barriers predomin-
ating in each phase. This study concentrates on the orien-
tation, insight and acceptance phases.
Barriers and facilitators
Although there are numerous studies concerning the
barriers and facilitators for CPG implementation [17],
this is not the case in our setting. As a result, before de-
signing the guideline implementation intervention, we
undertook a study to explore the barriers faced by CPGs
in primary care using the Delphi technique [18]. The
main barriers detected are the following [18].
Dimension: Presentation of the guidelines:
– The teaching method used by the speakers at each
session.
– The choice of speaker.
Dimension: Format of the guidelines:
– The need for a summarized version.
– The need to stimulate and promote the on-line
version, which makes term search easier, and the
links within the guidelines and to other material of
interest.
– The need to enhance user participation (discussion
fora, asking questions, debates, etc.).
Etxeberria et al. BMC Health Services Research 2013, 13:438 Page 3 of 7
http://www.biomedcentral.com/1472-6963/13/438Dimension: Use and utility facilitators:
– Application of CPGs gives good results in clinical
practice.
– The need to attach action protocols or other
practical tools to the guidelines.
Internal barriers:
– Willingness of the physicians themselves.
– Too much time and effort required to understand
the CPGs.
– Lack of acceptance of guidelines as a work tool.
– Discouragement due to lack of use at other
healthcare levels.
External barriers:
– Specialized practice does not follow the guidelines.
– Lack of dissemination and implementation in
specialized care.
– Pressure from the pharmaceutical industry.
– Methodology followed to learn the guidelines.
Effectiveness of guideline implementation interventions
According to Grimshaw’s systematic review [12], the ef-
fectiveness of different clinical practice guideline dissem-
ination and implementation strategies varies but, in
general, tends to be modest. The dissemination of edu-
cational materials tends to be poorly effective but at
low-cost, whereas continual medical training is more
effective if undertaken in small groups using realistic
scenarios [19-21]. The efficacy of opinion leader-based
training tends to vary [12]. Multifaceted interventions
appear to make sense if they are intended to overcome
specific barriers [19]. Indeed, tailored interventions are
more effective than passive guideline dissemination [13].
In the field of diabetes, the review by Shojania [22]
showed that multifaceted interventions provided a larger
effect than interventions involving a single compo-
nent. Educational interventions showed an acceptable
efficacy. In the field of hypertension, educational in-
terventions aimed at healthcare professionals resulted
in a modest improvement in blood pressure control
[23]. The most effective strategy for implementing the
use of risk tables in cardiovascular disease prevention
is still unknown [24].
Context
The intervention and study were designed in the context
of a primary care research group with a clinical and/
or methodological profile involved in the drafting and
implementation of evidence-based guidelines. The inter-
vention was aimed at primary care professionals (physi-
cians and nurses) and no organisational changes or
interventions in patients were considered. A further
assumption was that the proposed interventions had
to be feasible and result in a reasonable cost to the
health system.As no single implementation strategy is effective in all
contexts, the impact of such strategies needs to be evalu-
ated by way of studies with a robust design and low risk
of bias. Randomized designs are the gold-standard for
assessing healthcare interventions [12,25].
Although we are witnessing significant support for the
drafting of CPGs by public health organisations in Spain,
evaluation of their subsequent implementation remains
uncommon [26].
In our setting, the availability of three recently published
CPGs in the cardiovascular field provides a unique oppor-
tunity to assess CPG implementation strategies in primary
care.
Main endpoint
To evaluate the effectiveness of a multifaceted tailored
intervention in the implementation of three cardiovas-
cular risk-related CPGs (hypertension, type 2 diabetes
and lipids as cardiovascular risk factor) in primary
care in the Basque Health Service compared with usual
implementation.
Secondary endpoints
 To evaluate the impact of the intervention on the
degree of compliance with process quality indicators
and subrogate clinical endpoints for the care of
patients with type 2 diabetes.
 To evaluate the impact of the intervention on the
degree of compliance with process quality indicators
and subrogate clinical endpoints for the care of
patients with hypertension.
 To evaluate the impact of the intervention on the
degree of compliance with coronary risk screening
process quality indicators.
 To evaluate the impact of the intervention on the
prescription of statins in primary and secondary
prevention.
Methods/Design
Study design and setting
This study is a cluster randomized trial conducted in
two urban primary care districts in the Basque Health
Service (Ekialde and Bilbao). These districts cover 36.9%
of the population in the Basque Country. Primary care
units (PCU) will be randomly assigned.
A cluster-type design is selected as the intervention
was aimed at professionals working in a PCU and due to
the risk of contamination between professionals working
in the same PCU [27,28].
A repeated cross-sectional design is used for all pa-
tients who attend during the baseline period (pre-
intervention, or “PRE”) and in the post-intervention period
(“POST”), with different samples. Such an approach is
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impact of CPG implementation on the population and
provides greater long-term power [27,28]. It also allows
minor baseline differences that may arise due to cluster
randomization to be compensated. The study design is
shown in Figure 1.
Study population
Consent to participate was received from the heads of
all PCUs from both districts, therefore they were all ran-
domized (43 PCUs). All professionals (physicians and
nurses) appointed to medical jobs in family medicine
who agreed to participate in the study were included.
Data from all patients who attend their PCU during the
study period (PRE and POST intervention) and assigned
to the PCUs and physicians/nurses who participate in
the study will be analyzed, if they complied with one of
the following inclusion criteria:
– A diagnosis of type 2 diabetes in the medical record.
– A diagnosis of hypertension in the medical record.
– Population susceptible to cardiovascular risk
screening: women aged 45–74 years and men aged
40–74 years with no ischemic heart disease.Eligible PCUs: 43

















Data extraction and analysis
Figure 1 Study design.– Patients who commenced statin treatment during
the study period.
– Patients diagnosed with ischemic heart disease
during the study period.
The exclusion criteria are: patients assigned physicians
or nurses who declined to participate in the study, youn-
ger than 14 years of age, patients assigned to physicians
occupying two or more medical posts belonging to the
intervention and control groups at the same time, and
patients who don’t attend their PCU during the study
period.
Interventions
The control group will receive usual implementation,
namely mailing of the guideline, publication in the intra-
net and presentation sessions in the PCU. These sessions
will be led by physicians trained by the trainers respon-
sible for teaching the intervention group.
In addition to the control group interventions, the
multifaceted implementation for the experimental group
also includes:
– Identical presentation sessions to those for the
control group but given by physicians who took part
in the guideline development process.
– The design of a specific web page with the
guideline recommendations aimed at the action,
with quick access, application tools (algorithms
and tables with links to the main
recommendations, patient materials), the
possibility to ask questions, links to drug-related
information.
– Three-hour workshops for family physicians and
nurses, eight cardiovascular risk workshops for
family physicians and a further eight for nursing
staff, and four diabetic foot workshops for
nursing staff. These workshops will be mostly
led by the physicians responsible for the




– Diabetes: percentage of patients with annual request
for glycosylated haemoglobin (HbA1c).
– Hypertension: percentage of patients with annual
request for basic analysis, including albumin-
creatinine ratio.
– Dyslipidemia: males between 40–74 and females
between 45–74 years with at least one
cardiovascular risk assessment (except males and
females with cardiovascular disease).
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– Diabetes: percentage of patients with HbA1c lower
than 7%, percentage of patients with blood pressure
lower than 140/80 mm Hg, percentage of patients
with confirmed basic analysis, percentage of patients
with confirmed cardiovascular risk assessment,
percentage of patients with confirmed foot
examination and new pharmacological treatment
started with metformin.
– Hypertension: percentage of non-diabetic patients
with blood pressure lower than 140/90 mm Hg,
percentage of patients with annual cardiovascular
risk assessment, percentage of patients starting
pharmacological treatment with diuretics, beta-
blockers or angiotensin-II receptor blockers.
– Dyslipidemia: percentage of patients aged between
35 and 74 years with no cardiovascular disease
starting a statin treatment with previous
cardiovascular risk assessment, new statin
treatments in women aged over 35 years with no
cardiovascular disease or diabetes, percentage of
patients with a new diagnosis of coronary heart
disease receiving statin treatment.
Sample size
The following aspects were taken into account when cal-
culating the sample size:
 On average, 45-50% of diabetic patients assigned to
a healthcare professional undergo at least two
annual HbA1c analyses (standard deviation 15-20%).
An annual analysis is requested in around 35% of
hypertensive patients. (Data taken from the Provider
Agreement, 2007).
 From a clinical and operational viewpoint, an
intervention strategy would be worthwhile if these
averages could be increased to 55-60% for diabetes
and 43% for hypertension.
 The size of the PCUs is similar, with around 10
physicians per PCU, and the number of patients
assigned to each clinician is also similar.
 The intracluster correlation coefficient (ICC) is 0.10
[29-31].
In light of these considerations, approximately 100
physicians per group (10 PCUs in each group) would be
needed for an α of 0.05 and a β of 0.20. Applying the
cluster-related design effect gives a final number of 20
PCUs per group (intervention and control).
Randomization
Allocation is performed by clusters. PCUs are assigned to
the intervention or control group following a computer-generated randomization sequence. Randomization is per-
formed centrally by a researcher not involved in the study
who was blind to the identity of the PCU.
Masking
Professionals implementing the intervention are not
blinded to the assignment group. However, data extrac-
tion will be performed centrally by computer technicians
not involved in the study and data will be treated by re-
search personnel after anonymisation.
Analysis
Data will be extracted from centralized computerized
medical records. Analysis will be performed at the PCU
level taking the cluster design into account [32]. Indica-
tors will be obtained for each PCU before and after
the intervention and the differences will be weighted
by cluster size. All analyses will be performed using
Student’s t-test as implemented in SPSS 19. A sec-
ondary multi-level analysis will be performed using
MLwiN (version 2.21) to determine the intracluster
correlation coefficients (ICCs).
Analysis will be performed on an intention-to-treat
basis.
Ethical considerations
This trial was approved by the Clinical Research Ethics
Committee of the Basque Country. The protocol was regis-
tered in the Current Controlled Trials database (ISRCTN
88876909). Funding was provided by the Spanish Ministry
of Health as part of the 2007–2008 collaboration agree-
ment anticipated in the National Health System’s quality
plan between the Carlos III Research Institute, an autono-
mous body that forms part of the Spanish Ministry of
Science and Innovation, and the Basque Government’s
Department for Health and Consumer Affairs (OSTEBA).
Discussion
There is a growing need to identify effective implemen-
tation strategies for CPGs for the management of cardio-
vascular risk factors in primary care. This study is one of
the few cluster randomized trials concerning the imple-
mentation of clinical practice guidelines in Spanish pri-
mary care.
This study focuses on multiple cardiovascular risk fac-
tors as primary endpoints. Its pragmatic design is aimed
at determined the actual impact of implementing CPGs
for type 2 diabetes, hypertension and dyslipidemia via a
multifaceted intervention based on identifying local bar-
riers to CPG implementation, and it is aimed at primary
care professionals.
The limitations of this study include the use of medical
records as data source. Giving the nature of the study,
the intervention cannot be masked.
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CPG planning in the primary cardiovascular care field to
be designed. Similarly, it will allow the key aspects of
recommendation implementation in our setting to be
identified. All this information may prove useful in the
organisational transformation currently underway in the
Basque Country to adapt the health system to the care
needs of patients with chronic diseases.
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